Drug Profile
Cancer vaccine - Dow AgroSciences/Biomira
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Biomira; Dow AgroSciences
- Developer Biomira
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Sep 2004 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 05 Jul 2000 The assets and technology of Axis Genetics have been sold to Dow AgroSciences
- 10 Sep 1999 Axis Genetics has been placed into administration and a buyer is being sought for its business and assets